We are pleased to welcome all the interested participants to Neglected Tropical Diseases Conference: Current and Future Challenges during November 02-03, 2017 at Chicago, Illinois, USA. Tropical diseases 2017 welcomes all the members form universities, clinical examination foundations and research organizations, physicians, biologists, scientists, researchers, academicians, entrepreneurs, research scholars and delegates from research labs, industries and healthcare sectors to be a part of the conference to share their knowledge on all parts of this rapidly expanded field and then, by providing a showcase of the research in this field and making the efforts to conquer this battle of Neglected Tropical diseases which is burden to our human society.
The conference focuses on the theme "Improved Health Protection Paybacks for all".
Tropical Diseases 2017 aims to provide scientific platform for face to face exchange of knowledge and research ideas across these concerns for endemic diseases which is claiming havocs around the globe every year. The conference is designed to give knowledge, ideas and to think out of the box. The aim of the conference is to promote research in the field of neglected tropical diseases with another goal to facilitate exchange of new ideas in these fields and to create a dialogue between scientists, practitioners, health organizations to come together and overcome and conquer this situation.
Neglected Tropical Diseases (NTDs) are a diverse group of communicable diseases which almost covers 18 infectious diseases that are caused by bacteria, parasites, or viruses that more or less affect the poor societies generally affect children and causes significant health and financial burdens and across the underdeveloped nations. They mostly affect populations who are living in poverty, without proper sanitation and in close touch with various infectious vectors and disease causing livestock and animals. NTDs are very common and sometimes fatal and they regularly infect humans. Over 150 countries, with almost over 1 billion people are currently infected and over 2 billion people at verge of risk and are responsible for millions of deaths and disabilities each year, around the globe. According to the reports from World Health Organization (WHO), the major diseases of concern are malaria, which affects more than one third of the world’s population, and have killing more than 1 million children every year; visceral leishmaniasis, affecting about 12 million people and Chagas disease, affecting 18 million people in Latin America alone which sleeping sickness (African trypanosomiasis), which affects half a million people each year.
These diseases are generally preventable and treatable through control of the insects that carry these diseases, improved sanitation, fresh and clean water quality, and the proper health awareness along with the efficient delivery of drug treatments. Controlling NTDs is very prominent and requires major steps which would not only reduce disease burden but would also improve maternal health, reduce childhood mortality, reduce malnutrition, and help to improve school attendance.
Of the 850 new therapeutic products registered in 2000–2011, only 5 (0.6%) were indicated for NTDs, none of them being a new chemical entity (NCE) or vaccine. It is quite surprising that Ebola is officially classed as a ‘neglected tropical disease’ although recent outbreaks are the worst on records and interestingly between 1976 and 2013 there occurs 26 outbreaks of the virus, mainly occurred in sub-Saharan African nations, resulting in a total of around 1,710 cases. We can clearly see the comparison and level of difference between Ebola outbreak and the current Chikungunya outbreak and the level of media and news hype that estimated to have infected around 900,000 people in Americas only.
In January 2012, WHO, the Bill & Melinda Gates Foundation, political members from several states, Managing Directors from the various pharmaceutical industry provided a vision known as the London Declaration on Neglected Tropical Diseases. They pledged to sustain, expand, and extend the drug supply; (b) accelerate research and development for new treatments; and (c) increase funding to improve implementation to control or eliminate 10 NTDs.
The U.S. Agency for International Development has recently announced a five year, $100 million fund to provide some major preventive drugs for 40 million people, while Geneva Global has committed $8.8 million for preventive chemotherapy in Rwanda and Burundi which will help in combating these burdens.
The Bill and Melinda Gates Foundation have awarded $47 million to acknowledge and discuss the prominent questions regarding research and development for effective amalgamation. However, these awards are not so sufficient enough compared to overall costs required to meet up the needs in the areas of sub-Saharan Africa and elsewhere around the globe. It is estimated that approximately $1 billion to $2 billion fund must be needed within a five year program to control or somewhat eliminate the major neglected tropical diseases in sub-Saharan Africa.
Why to attend??
With members from around the world focused on learning more about the tropical diseases treatment and their management. This conference will provide the best platform and the best occasion to outreach the great gathering of participants from around the world. This scientific stage will provide an opportunity to the scientists, researchers to conduct presentations, exchange and update knowledge about the current situation of neglected tropical diseases treatment and receive recognition on global platform and join hands for this global human cause.
· Health Care Professionals
· Infectious Diseases Researchers, Scientists, Faculties, Students
· Infectious Diseases Associations and Societies
· Drug Manufacturing Companies and Industries
· Laboratory Technicians and Diagnostic Companies
Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies. This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).
Market Analysis for NTD
Six of the world’s ten largest pharmaceutical companies are based in the United States, and the remaining four are in Europe according to WHO 2016 reports. The world has conventionally very much relied on the expertise of private owned corporations for the production of pharmaceuticals and these companies has the powerful impact on the economic sectors in global health.
From the Food and Drug Administration (FDA) in the US, only the industry reports over half a trillion dollars’ worth of investment in research into development of new medicines since 2000, and over 500 new medicines have successfully granted marketing approval during that same time period (PhRMA 2016).The pharmaceutical market is worth US$300 billion per year and several other individual companies have profit margins exceeding 30%, making their yearly profits above US$10 billion and they provide almost everything from lifesaving drugs to other required therapies around the world.
Total United State Government funding for NTDs increased from $15 million in 2006, which was the first year Congress appropriated funds for NTDs, to $100 million in Funding Year 2016. The President’s Funding Year 2017 budget request included $86.5 million for NTDs. If approved by Congress, this would be a $13.5 million (14%) decrease from the Funding Year 2016 enacted level.